AlloVir, Inc. (ALVR)
| Market Cap | 1.46B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -117.32M |
| Shares Out | 65.12M |
| EPS (ttm) | -2.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 89,265 |
| Open | 22.64 |
| Previous Close | 22.47 |
| Day's Range | 22.09 - 23.39 |
| 52-Week Range | 16.66 - 48.96 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 45.75 (+96.0%) |
| Est. Earnings Date | Nov 5, 2021 |
About ALVR
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is Viralym-M, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, and human herpesvirus 6. Its preclinical and clinical development product candidates include ALVR106 for respiratory syncytial virus, influenza, parainfluenza virus, and hu...
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for AlloVir stock is "Buy." The 12-month stock price forecast is 45.75, which is an increase of 96.02% from the latest price.
News
AlloVir to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate update at the Morgan Stanley 19th Annual Global Healthcare Conferenc...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fid...
New York, New York--(Newsfile Corp. - August 26, 2021) - Levi & Korsinsky announces it has commenced an investigation of Avalara, Inc. (NASDAQ: ALVR) concerning possible breaches of fiduciary duty. To o...
AlloVir Reports Second Quarter 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30, 2021....
AlloVir Reports First Quarter 2021 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the first quarter ended March 31, 2021....
AlloVir Appoints Diana M. Brainard, M.D.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced today that its Board of Directors has appointed Diana M. Brainard, M.D., as the company's...
AlloVir to Present at the 10th Annual SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 10th Annual SVB Leerink Globa...
AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced results of a subgroup analysis from a Phase 2, proof-of-conc...
AlloVir Reports Full Year 2020 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today provided a corporate update and reported full-year 2020 financial resu...
U.S. IPO Week Ahead: Diverse 8 IPO Week Features 3 Billion-Dollar Deals
The US IPO market is expected to remain active in the week ahead with eight IPOs slated to raise $4.6 billion. Street research is expected for Medirom Healthcare Technologies on Monday, 1/25.
AlloVir Announces Data Presentations at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three oral presentations and one poster prese...
AlloVir to Present at the 39th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #celltherapy--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the 39th Annual J.P. Morgan Healt...
AlloVir Announces FDA Clearance of Investigational New Drug Application for ALVR106, an Allogeneic, Off-the-Shelf, Mu...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that the U.S. Food and Drug Administration (FDA) has cleared the Investi...
Company Profile for AlloVir
--(BUSINESS WIRE)--AlloVir is a leading late clinical-stage cell therapy company with a focus on restoring natural immunity against life-threatening viral diseases in patients with severely weakened imm...
Positive Phase 2 Proof-of-Concept Data for Viralym-M and Burden of Disease Data Presented in Oral Presentations at th...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that results from the Phase 2, proof-of-concept CHARMS study demon...
Preclinical Data Demonstrate Anti-Viral Activity of AlloVir's ALVR109, an Allogeneic, Off-the-Shelf SARS-CoV-2 Specif...
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ALVR #ASH20--AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that preclinical data presented in an oral presentation at the 62n...
AlloVir to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the Piper Sandler 32nd Annual Virtual Healthcare Confere...
AlloVir Announces Oral Data Presentations at 62nd American Society of Hematology Annual Meeting
CAMBRIDGE, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three abstracts as oral presentations that support ...
Data to Be Presented at IDWeek™ 2020 Demonstrate the Economic and Clinical Burden of Respiratory and Multi-Virus Infe...
Findings Demonstrate Significantly Higher Health Care Costs, Health Resource Utilization, and Worse Clinical Outcomes Among Allo-HCT Patients with Viral Infections Findings Demonstrate Significantly Hig...
AlloVir Announces the FDA Clearance of Investigational New Drug Application (IND) for ALVR109 for the Treatment of Hi...
- ALVR109 is an allogeneic, off-the-shelf virus-specific T cell therapy candidate designed to target SARS-CoV-2 for high-risk COVID-19 patients
AlloVir Appoints Ercem Atillasoy, M.D., as Chief Regulatory and Safety Officer
Appointment Expands AlloVir’s Regulatory Expertise as Company Plans to Initiate Multiple Pivotal and Proof-of-Concept Trials Appointment Expands AlloVir’s Regulatory Expertise as Company Plans to Initia...
AlloVir Reports Second Quarter 2020 Financial Results
CAMBRIDGE, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today reported financial results for the second quarter ended June 30, 2020.
AlloVir to Present at the Morgan Stanley 18th Annual Global Healthcare Conference
CAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, will present a corporate overview at the virtual Morgan Stanley 18th Annua...
AlloVir Shares Skyrocket Following IPO
Stock of virus therapy biotech up more than 70% in just a few days
AlloVir Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchas...
CAMBRIDGE, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- AlloVir, Inc. (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced the closing of its upsized initial public offering of 18,6...